0
Il n'y a pas de produit dans le panier !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Accueil > Protein > IL-17A > ILA-H5219

Human IL-17A / CTLA-8 Protein, premium grade

Order Now

  • Synonym
    IL-17A,Interleukin-17A,CTLA-8,IL-17
  • Source
    Human IL17A, premium grade(ILA-H5219) is expressed from human 293 cells (HEK293). It contains AA Gly 24 - Ala 155 (Accession # Q16552-1).
    Predicted N-terminus: Gly 24
    Human IL17A, premium grade (ILA-H5219), designed for preclinical stage, has the same activity and performance with GMP Human IL-17A, which enables a seamless transition from preclinical development to clinical phases. Premium Grade product offer a cost efficient alternative of GMP Grade products for the early development phase when safety of raw materials is not top priority. By using Premium Grade products in early development phase, you can transition easily into clinical and commercial phase without need to revalidate the raw materials and modify manufacturing process.
  • Molecular Characterization
    IL-17A Structure

    This protein carries no "tag".

    The protein has a calculated MW of 15.1 kDa. The protein migrates as 16 kDa, 17 kDa and 19 kDa under reducing (R) condition, and 27-34 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under non-reducing (NR) condition (SDS-PAGE) due to glycosylation.

  • Endotoxin
    Less than 0.1 EU per μg by the LAL method.
  • Sterility
    Negative
  • Mycoplasma
    Negative.
  • Purity

    >90% as determined by SDS-PAGE.

    >95% as determined by SEC-MALS.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
SDS-PAGE
IL-17A SDS-PAGE

Human IL17A, premium grade on SDS-PAGE under reducing (R) and non-reducing (NR) conditions. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With Star Ribbon Pre-stained Protein Marker).

SEC-MALS
IL-17A MALS images

The purity of Human IL17A, premium grade (Cat. No. ILA-H5219) is more than 95% and the molecular weight of this protein is around 30-46 kDa verified by SEC-MALS.

Bioactivity-Bioactivity CELL BASE
 IL-17A CELL

Human IL-17A, premium grade (Cat. No. ILA-H5219) stimulates proliferation of 293F-NFKB/luc-IL17-30 cell line. The specific activity of Human IL-17A, premium grade is > 1.00ⅹ10^7 IU/mg, which is calibrated against human IL-17 WHO International Standard (NIBSC code: 01/420) (QC tested).

Bioactivity-ELISA
 IL-17A ELISA

Immobilized Human IL17A, premium grade (Cat. No. ILA-H5219) at 0.5 μg/mL (100 μL/well) can bind Human IL-17 RA, His Tag (Cat. No. ILA-H5222) with a linear range of 8-125 ng/mL (QC tested).

  • Background
    Interleukin-17A (IL17A) is also known as cytotoxic T-lymphocyte-associated antigen 8 (CTLA8),which is a proinflammatory cytokine produced by activated T cells. IL17A can regulate the activities of NF-kappaB and mitogen-activated protein kinases. Also,IL17A can stimulate the expression of IL6 and cyclooxygenase-2 (PTGS2/COX-2), as well as enhance the production of nitric oxide (NO).Furthermore,IL17A has been found both in glycosylated and nonglycosylated forms. High levels of IL-17 are associated with several chronic inflammatory diseases including rheumatoid arthritis, psoriasis and multiple sclerosis.
  • Clinical and Translational Updates

Comments (0)


ETA des produits en stock: 2 jours ouvrables

Price(EUR) : €130.00

Price(EUR) : €350.00

Price(EUR) : €2570.00

Promotion & Exhibitions



Drug Development Status

  • Number of Launched Drugs:3 Details
  • Number of Drugs in Clinical Trials:29 Details
  • Latest Research Phase:Approved

Datasheet & Documentation

Request for DMF
DMF (Drug Master File)

New Product Launch

Questions & Comments

This web search service is supported by Google Inc.

totop

Laisser un message